Tags

Type your tag names separated by a space and hit enter

Aripiprazole-induced parkinsonism.
Int Clin Psychopharmacol. 2006 Mar; 21(2):127-9.IC

Abstract

Dopamine receptor antagonism is associated not only with antipsychotic action, but also with the generation of extrapyramidal side-effects of antipsychotic medications. Positron emission tomography studies reveal that an approximate 60-70% blockade of the D2 receptors is required for typical antipsychotics to be efficacious, but a blockade of > or =75-80% results in acute extrapyramidal side-effects. The newer atypical antipsychotics have a lower propensity to produce extrapyramidal side-effects. A new class of antipsychotics with a novel pharmacological profile and improved tolerability have emerged, comprising the 'dopamine-serotonin system stabilizers' of which aripiprazole is the first agent. We present the case of a patient who developed parkinsonism during treatment with aripiprazole.

Authors+Show Affiliations

Department of Psychiatry, University of Nebraska Medical Center, Omaha, 68198, USA. doctorshama@hotmail.comNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

16421466

Citation

Sharma, Ashish, and James H. Sorrell. "Aripiprazole-induced Parkinsonism." International Clinical Psychopharmacology, vol. 21, no. 2, 2006, pp. 127-9.
Sharma A, Sorrell JH. Aripiprazole-induced parkinsonism. Int Clin Psychopharmacol. 2006;21(2):127-9.
Sharma, A., & Sorrell, J. H. (2006). Aripiprazole-induced parkinsonism. International Clinical Psychopharmacology, 21(2), 127-9.
Sharma A, Sorrell JH. Aripiprazole-induced Parkinsonism. Int Clin Psychopharmacol. 2006;21(2):127-9. PubMed PMID: 16421466.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aripiprazole-induced parkinsonism. AU - Sharma,Ashish, AU - Sorrell,James H, PY - 2006/1/20/pubmed PY - 2006/3/29/medline PY - 2006/1/20/entrez SP - 127 EP - 9 JF - International clinical psychopharmacology JO - Int Clin Psychopharmacol VL - 21 IS - 2 N2 - Dopamine receptor antagonism is associated not only with antipsychotic action, but also with the generation of extrapyramidal side-effects of antipsychotic medications. Positron emission tomography studies reveal that an approximate 60-70% blockade of the D2 receptors is required for typical antipsychotics to be efficacious, but a blockade of > or =75-80% results in acute extrapyramidal side-effects. The newer atypical antipsychotics have a lower propensity to produce extrapyramidal side-effects. A new class of antipsychotics with a novel pharmacological profile and improved tolerability have emerged, comprising the 'dopamine-serotonin system stabilizers' of which aripiprazole is the first agent. We present the case of a patient who developed parkinsonism during treatment with aripiprazole. SN - 0268-1315 UR - https://www.unboundmedicine.com/medline/citation/16421466/Aripiprazole_induced_parkinsonism_ L2 - https://doi.org/10.1097/01.yic.0000185025.40656.30 DB - PRIME DP - Unbound Medicine ER -